Application of selective CDK4/6 inhibitors in solid cancers therapy / 国际肿瘤学杂志

ABSTRACT

Cyclin-dependent kinase (CDK) inhibitors have been approved for the treatment of ER +/HER2-advanced breast cancer,and preclinical study and clinical trials are under way for multiple solid cancers.CDK4/6 inhibitors have shown good efficacy for human solid cancers,and it's future development direction are biomarkers,drug resistance and combined therapy in the future.